Paroxetine suppresses recombinant human P2X7 responses

Phuong Dao-Ung¹ · Kristen K. Skarratt¹ · Stephen J. Fuller¹ · Leanne Stokes^{1,2}

Received: 5 June 2015 / Accepted: 24 August 2015 / Published online: 5 September 2015
© Springer Science+Business Media Dordrecht 2015

Abstract P2X7 receptor (P2X7) activity may link inflammation to depressive disorders. Genetic variants of human P2X7 have been linked with major depression and bipolar disorders, and the P2X7 knockout mouse has been shown to exhibit anti-depressive-like behaviour. P2X7 is an ATP-gated ion channel and is a major regulator of the pro-inflammatory cytokine interleukin 1 β (IL-1 β) secretion from monocytes and microglia. We hypothesised that antidepressants may elicit their mood enhancing effects in part via modulating P2X7 activity and reducing inflammatory responses. In this study, we determined whether common psychoactive drugs could affect recombinant and native human P2X7 responses in vitro. Common antidepressants demonstrated opposing effects on human P2X7-mediated responses; paroxetine inhibited while fluoxetine and clomipramine mildly potentiated ATP-induced dye uptake in HEK-293 cells stably expressing recombinant human P2X7. Paroxetine inhibited dye uptake mediated by human P2X7 in a concentration-dependent manner with an IC₅₀ of 24 μ M and significantly reduces ATP-induced inward currents. We confirmed that trifluoperazine hydrochloride suppressed human P2X7 responses (IC₅₀ of 6.4 μ M). Both paroxetine and trifluoperazine did not inhibit rodent P2X7 responses, and mutation of a known residue (F 95L) did not alter the effect of either drug, suggesting neither drug binds at this site. Finally, we demonstrate that P2X7-induced IL-1 β

secretion from lipopolysaccharide (LPS)-primed human CD14⁺ monocytes was suppressed with trifluoperazine and paroxetine.

Keywords P2X7 · Antidepressant · Paroxetine · Fluoxetine · Trifluoperazine · Interleukin 1 β · ATP

Abbreviations

SSRI Selective serotonin reuptake inhibitor
IL-1 β Interleukin 1 beta
LPS Lipopolysaccharide

Introduction

The P2X7 receptor (P2X7) is a ligand-gated ion channel activated by extracellular ATP and is highly expressed on myeloid cells, including monocytes, macrophages, dendritic cells and microglia, amongst other cell types including neurons and astrocytes [1]. Sustained activation of P2X7 can induce a variety of downstream signalling events and is a major physiological stimulus for the rapid secretion of pro-inflammatory cytokines of the interleukin-1 family including interleukin-1 β (IL-1 β) and interleukin-18 (IL-18) [2, 3]. Pro-inflammatory cytokines, including IL-1 β , induce sickness behaviour with depression-like symptoms in animals, and an association between inflammation and depression is now well accepted [4–6]. Consequently, regulation of IL-1 β by the P2X7 receptor may be critical in the pathophysiology of depression and this could have important applications for P2X7 as a pharmacological target.

Genetic association studies have found some associations between P2X7 variants and mood disorders. A non-synonymous single nucleotide polymorphism (SNP) in

✉ Leanne Stokes
l.stokes@uea.ac.uk

¹ Sydney Medical School Nepean, University of Sydney, Nepean Hospital, Level 5 South Block, Derby Street, Penrith, NSW 2750, Australia

² School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK

P2RX7, rs2230912 encoding the amino acid change Q460>R, has been linked to major depression and bipolar disorder in some, but not all, genetic studies [7–13]. This SNP is inherited on a gain-of-function *P2RX7* haplotype, and monocytes from healthy individuals carrying this gain-of-function haplotype displayed enhanced *P2RX7*-mediated IL-1 β secretion [14]. In addition, it is known that the *P2RX7* knockout mouse has an anti-depressive phenotype [15, 16]. The expression of *P2RX7* in neurons is still debatable and therefore whether this anti-depressive phenotype is due to a reduced inflammatory capacity in central glial cells is currently unclear [17].

The aim of the present study was to investigate the effect of commonly prescribed psychoactive drugs on *P2RX7* responses in vitro. *P2RX7* receptors are known to bind a wide range of drug molecules displaying antagonism or potentiation of receptor responses (reviewed in [18, 19]). In addition to recently developed selective *P2RX7* antagonists, unrelated compounds such as KN-62 [20], calmidazolium [21], chelerythrine [22], a

tyrosine kinase inhibitor [23], SB203580 [24], DIDS [25], clemastine [26] and probenecid [27] can also inhibit or potentiate *P2RX7* receptor responses. The related purinergic ion channel *P2X4* is known to be blocked by several antidepressants with paroxetine, a selective serotonin reuptake inhibitor (SSRI), demonstrating the strongest inhibition [28]. The phenothiazine group of anti-psychotic agents including trifluoperazine have also recently been demonstrated to effectively block human *P2RX7* responses [29]; however, it is not known if *P2RX7* responses are inhibited by other antidepressant and mood stabilising compounds. Some antidepressants have been demonstrated to have anti-inflammatory effects in vitro although their mechanism of action is unknown [4, 30]. Here, we demonstrate that paroxetine is the only antidepressant to suppress recombinant human *P2RX7* responses and we investigated the anti-inflammatory efficacy of paroxetine and trifluoperazine in blocking IL-1 β secretion from human primary monocytes.

Fig. 1 The effect of antidepressants on recombinant human *P2RX7*. **a** Ethidium⁺ uptake was induced in HEK-h*P2RX7* expressing cells by the addition of 1 mM ATP (denoted by the arrow) in a low divalent physiological solution. Fluorescence was measured using a Fluostar Optima plate reader over a 300-second recording. Cells were pre-incubated with drugs for 10 mins at 37 °C before ATP addition. Dye uptake in response to ATP is shown in black and in the presence of paroxetine (PAR) in red shapes. **b** Concentration response curve for

inhibition of ATP-induced ethidium⁺ uptake by paroxetine (red) and the selective *P2RX7* antagonist, A-438079 (black). **c** Ethidium⁺ uptake to ATP in HEK-h*P2RX7* cells in the presence of 30 μM fluoxetine (FLUOX) (blue) or 30 μM clomipramine (CLOM) (green). **d** Bar chart demonstrating mild potentiation of ATP-induced dye uptake by fluoxetine and significant potentiation by clomipramine ($n=3$ independent experiments). **e** Chemical structures of paroxetine, fluoxetine and clomipramine. * $P<0.05$ (ANOVA)

Methods

Materials

ATP, ethidium bromide, paroxetine maleate, paroxetine hydrochloride, fluoxetine hydrochloride, clomipramine hydrochloride, carbamazepine, lithium chloride, sodium valproate and trifluoperazine hydrochloride were all from Sigma-Aldrich (St. Louis, MO, USA). A-438079 hydrochloride and AZ11645373 were from Tocris Biosciences (Bristol, UK). Poly-D-lysine was from Merck Millipore (Billerica, MA, USA). Geneticin (G418) was from Life Technologies Australia.

Cell culture and transfection

HEK-293 cells were maintained in DMEM: F12 media (Life Technologies Australia) supplemented with 10 % foetal bovine serum (Lonza Australia Pty Ltd, VIC, Australia), 100 U/ml penicillin, 100 µg/ml streptomycin and 5 mM L-glutamine (Life Technologies Australia). Stable cell lines expressing the human P2X7 receptor, rat P2X7 receptor and mouse P2X7 receptor were established by clonal dilution and kept under G418 selection media (Life Technologies Australia). Transient transfections were performed in 35-mm Petri dishes

using 1 µg plasmid DNA and Lipofectamine 2000 (Life Technologies Australia) as per manufacturer's instructions.

Molecular biology

The wild-type human P2X7, rat P2X7 and mouse P2X7 constructs were obtained from Professors Annmarie Surprenant and Alan North, University of Manchester, UK. The human P2X7 gain-of-function variant termed P2X7-4 was used previously [14] and contains a combination of H155Y, H270R, A348T and Q460R mutations. All constructs were verified by sequencing (SUPAMAC, University of Sydney, NSW, Australia).

Isolation of human monocytes

Peripheral venous blood was collected from genotyped healthy volunteers (both male and females) into heparin vacutainers (Becton Dickinson, NJ, USA). Written consent was obtained from each participant, and the study was approved by the Nepean and Blue Mountains Local Health Network Human Ethics Committee Protocol No. 10/40-AU RED HREC/010/NEPEAN/89. All donors carried the gain-of-function SNP rs1718119 encoding the A348T mutation [14]. Mononuclear cells were isolated using Ficoll-Paque density centrifugation.

Fig. 2 Trifluoperazine hydrochloride acts on human P2X7 responses. **a** Ethidium⁺ uptake was induced in HEK-hP2X7 expressing cells by the addition of 1 mM ATP (denoted by the *arrow*) in a low divalent physiological solution. Fluorescence was measured using a Fluostar Optima plate reader over a 300-second recording. Trifluoperazine (TFP; 10 µM) was pre-incubated for 10 min at 37 °C before ATP addition, and dye uptake in response to ATP is shown in *black dots* and in the presence of ATP and TFP in *orange squares*. **b** Concentration response curve for inhibition of ATP-induced ethidium⁺ uptake by TFP. Inhibition of P2X7 by 10 and 30 µM was significant ($p < 0.01$ by ANOVA with Dunnett's post-test, $n = 4$ experiments). **c** Chemical structure of TFP

CD14 positive monocytes were isolated by positive selection microbeads and MS columns (Miltenyi Biotech, Bergisch Gladbach, Germany) as per manufacturer's instructions.

Dye uptake experiments

Stably transfected HEK-293 cells were plated into alternate wells of poly-D-lysine-coated 96 well plates (BD Falcon) at a density of 5×10^4 cells/well. The following day, media was replaced with low divalent buffer (145 mM NaCl, 5 mM KCl, 13 mM D-glucose, 10 mM HEPES and 0.1 mM CaCl_2 , pH 7.3) containing 25 μM ethidium bromide. Cells were pre-incubated with drugs for 10 min at 37 °C before the dye uptake assay was performed using a Fluostar Optima fluorescent plate reader (BMG Labtech GmbH, Ortenberg Germany) with excitation/emission filters 485 and 510 nm, respectively. Gain settings were constant throughout each experiment. Basal fluorescence measurements were acquired for 40 s followed by automatic injection of ATP (1 mM), and the kinetic measurement of fluorescence was performed for 4–10 min.

Electrophysiology

Whole-cell patch clamp recordings were performed at room temperature using an EPC10 amplifier and Patchmaster acquisition software (HEKA, Lambrecht, Germany). Agonists and drugs were delivered using the RSC-160 fast-flow system (Bio-Logic Science Instruments, France). Membrane potential was clamped at -60 mV in all experiments. External bath solution was 145 mM NaCl, 5 mM KCl, 2 mM CaCl_2 , 1 mM MgCl_2 , 13 mM D-glucose and 10 mM HEPES, and internal solution was 145 mM NaCl, 10 mM HEPES and 10 mM EGTA. Agonist was applied in a low divalent buffer as described for dye uptake experiments. All solutions were adjusted to pH 7.3 with 5 M NaOH and were 295–310 mosm/L.

IL-1 β secretion assays

Purified CD14 positive human monocytes were plated at a cell density of 2×10^5 cells/well in a total volume of 250 μl RPMI 1640 medium containing 1 % FCS. Cells were primed with

Fig. 3 Effect of antidepressants and TFP on rodent P2X7 responses. **a** Ethidium⁺ uptake was induced in HEK-rP2X7 and **b** HEK-mP2X7 stable expressing cells by the addition of 1 mM ATP (denoted by the arrow) in a low divalent physiological solution. Fluorescence was measured using a Fluostar Optima plate reader over a 300-second recording timeframe. Drugs were pre-incubated for 10 min at 37 °C before ATP addition.

Control dye uptake response to ATP in the absence of drugs is shown in black. Dye uptake responses in the presence of paroxetine (PAR; red), fluoxetine (FLOUX; blue), clomipramine (CLOM; green) and TFP (orange). Mean data from three independent experiments is summarised in (c) using the same colour coding

100 ng/ml lipopolysaccharide (LPS) for 4 h or medium alone (control) and were stimulated in duplicate. Drugs were added at the same time as LPS unless otherwise stated. ATP (3 mM) was added for 15 min and, following ATP stimulation, medium was removed from wells into clean eppendorf tubes. Supernatants were centrifuged briefly (60 secs) at $10,000\times g$ to remove any non-adherent cells, and the resultant cell-free supernatants were stored at -80°C . A paired ELISA antibody set (BD Biosciences, San Jose, CA, USA) for human IL-1 β was used to detect IL-1 β in cell supernatants. Ninety-six well plates were coated overnight with a capture anti-IL-1 β antibody, and a biotinylated anti-IL-1 β antibody was used for detection at the concentrations recommended by the manufacturer. Recombinant human IL-1 β was used as standard over the concentration range 4–250 pg/ml. Supernatants were diluted 1:50 in assay diluent (PBS containing 10 % FCS).

Statistical analysis

Data plotted are mean $\pm$ SEM of three to four experiments. Graphs and statistical analysis was performed using

GraphPad Prism version 6 (GraphPad Software Inc., La Jolla, CA, USA). Statistical significance was assessed using unpaired *t* tests or ANOVA with multiple comparison post-tests where appropriate. Significance was taken as $p < 0.05$ and is reported in figure legends.

Results

Our primary aim in this study was to determine whether psychoactive drugs for treatment of mood disorders such as depression and schizophrenia could affect human P2X7 responses in vitro. We screened HEK-293 cells stably expressing human P2X7 (HEK-hP2X7) in a dye uptake assay using ethidium bromide to measure the ATP-induced secondary permeability pathway. This has been used extensively to screen the effects of many compounds on P2X7 [19]. We tested three common antidepressants paroxetine, fluoxetine and clomipramine over the concentration range 10 nM–100 μM . We found that paroxetine at concentrations $>1\text{ }\mu\text{M}$ could inhibit the ATP-induced dye uptake in HEK-hP2X7 cells (Fig. 1). Further

Fig. 4 Residue 95 is not involved in paroxetine or TFP effect.

Ethidium⁺ uptake was measured in HEK-rP2X7 and HEK-rP2X7–95F mutant transiently transfected cells. The human-specific P2X7 antagonist AZ11645373 (purple) does not inhibit wild-type rP2X7; however, mutation of L95 causes AZ11645373 to become effective at rP2X7. No inhibitory effect was seen for TFP or paroxetine in rP2X7-95F (lower panel). Representative uptake curves from two separate transfections are shown

experiments revealed the IC_{50} value for paroxetine on hP2X7-induced dye uptake to be $24 \mu\text{M}$ (95 % confidence interval $18.5\text{--}31.7 \mu\text{M}$, $n=3$ independent experiments). In comparison, the IC_{50} value for the selective P2X7 antagonist A-438079 was $0.5 \mu\text{M}$ (95 % confidence interval $0.41\text{--}0.61 \mu\text{M}$, $n=3$ experiments) (Fig. 1b). This correlated well with other published data [31, 32]. In contrast, a second SSRI fluoxetine, and a tricyclic antidepressant clomipramine, had no inhibitory effects on P2X7 responses. A small potentiation of ATP-induced dye uptake was seen with $30 \mu\text{M}$ fluoxetine, and significant potentiation was seen with $30 \mu\text{M}$ clomipramine (Fig. 1c, d).

In addition to common antidepressants, we tested several mood stabilising and psychoactive drugs for their effect on human P2X7 responses including lithium chloride ($1 \mu\text{M}$ – 1mM), carbamazepine ($0.1\text{--}100 \mu\text{M}$), sodium valproate ($10 \mu\text{M}$ – 1mM) (data not shown) and trifluoperazine hydrochloride (100nM – $100 \mu\text{M}$). Of these, only trifluoperazine hydrochloride (TFP) showed a significant inhibitory effect on human P2X7 receptors (Fig. 2). In our hands, the IC_{50} value for inhibition of hP2X7-induced dye uptake by TFP was $6.4 \mu\text{M}$ (95 % confidence interval $5.6\text{--}7.3 \mu\text{M}$, $n=3$ experiments) which is slightly higher than previously reported [29].

Many compounds acting on human P2X7 have marked species selectivity [27, 33, 34]. We therefore investigated the effects of paroxetine, trifluoperazine, fluoxetine and clomipramine on recombinant rodent P2X7 receptors stably expressed in HEK-293 cells. Paroxetine and TFP showed no significant inhibitory effect on either rat P2X7 or mouse P2X7 (Fig. 3). Similar to human P2X7, fluoxetine and clomipramine mildly potentiated the response at both rat and mouse P2X7 (Fig. 3). Mean data is summarised in a bar chart (Fig. 3c).

Previous work from Michel and colleagues have shown that a potential binding site for human-specific P2X7 antagonists exists around amino acid residue 95 in the large ectodomain region of P2X7 [33]. We mutated the rat P2X7 at this position to the human equivalent (L>F) and determined whether this introduced sensitivity to paroxetine and TFP. We used AZ11645373 as a control since it has been demonstrated that this residue is involved in binding this human selective P2X7 antagonist [33]. We confirmed that wild-type rat P2X7 is not blocked by $100 \mu\text{M}$ AZ11645373 but that the rat P2X7-95F mutant displays increased sensitivity to AZ11645373 (Fig. 4). However, we found no increase in sensitivity to paroxetine or TFP in the rat P2X7-95F mutant (Fig. 4).

Fig. 5 Paroxetine and TFP inhibit recombinant gain-of-function P2X7 variant to a similar degree as wild-type P2X7. **a** Bar chart showing percentage of control response to ATP in the presence of $10 \mu\text{M}$ PAR, $40 \mu\text{M}$ PAR or $10 \mu\text{M}$ TFP for wild-type hP2X7 (black bars) and the P2X7-4.1 variant (white bars). * $p<0.05$ and ** $p<0.01$ from ANOVA with Dunnett's post-test, $n=3\text{--}4$ independent experiments. **b** A representative ATP-induced ethidium uptake plot demonstrating that $40 \mu\text{M}$ PAR (white squares) reduces the P2X7-4 variant response to

ATP (black squares) to a level similar to that of WT hP2X7 response to 1mM ATP (black circles). **c** Inward currents were recorded using whole-cell patch clamp in HEK-hP2X7. Cells were voltage clamped at -60mV . Responses were elicited using 1mM ATP for 5s before and after treatment with $30 \mu\text{M}$ PAR (5min). ATP was added in low divalent solution in the continued presence of PAR. Representative traces from three independent experiments are shown. Error bars represent standard error of the mean (SEM), * $p<0.05$ (unpaired t test)

Given the species selectivity of the paroxetine effect and its limitation to human P2X7, we decided to investigate whether the efficacy of paroxetine was different at a gain-of-function human P2X7 variant containing the Q 460>R mutation implicated in depressive disorders. We tested paroxetine and TFP on a P2X7-4.1 variant [14] expressed in HEK-293 cells and compared the level of inhibition to that of wild-type human P2X7. We found that paroxetine and TFP still inhibited responses at this gain-of-function variant, and there was no significant difference in the degree of inhibition at 40 μ M paroxetine or 10 μ M TFP (Fig. 5a).

To determine whether paroxetine binds to the human P2X7 receptor to block opening of the non-selective ion channel rather than having an effect on the secondary pore pathway directly, we performed patch clamp experiments on HEK-hP2X7 cells. Inward currents were recorded in response to a 5-s pulse of 1 mM ATP in low divalent extracellular solution in the absence of paroxetine (30 μ M) and then following exposure to paroxetine for 5 min (Fig. 5c). The ATP-induced inward current was significantly reduced to 28.9 ± 5.9 % of control by 30 μ M paroxetine ($n=4$ cells), suggesting that paroxetine binds to and blocks the P2X7 receptor directly.

One of the most physiological and likely pathophysiological consequences of P2X7 activation is the induction of IL-1 β secretion from monocytes, macrophages and microglia. We determined whether the inhibition of proximal receptor signalling by paroxetine or TFP would translate to a reduction in cytokine secretion from freshly isolated human monocytes. We studied ATP-induced IL-1 β secretion from three donors. LPS (100 ng/ml) was used to prime human CD14⁺ monocytes to generate pro-IL-1 β protein over a 4-h incubation period, and 3 mM ATP was used to induce cytokine secretion for a 15-min period as previously described [14]. All drugs were added during the LPS priming step. The P2X7 antagonist A-438079 (10 μ M) significantly blocked ATP-induced IL-1 β secretion by >95 % in all donors (Fig. 6). TFP (10 μ M) was also effective in blocking ATP-induced IL-1 β secretion by >95 % in all donors. Paroxetine (30 μ M) reduced P2X7-mediated IL-1 β secretion to 39 ± 14.3 % of the ATP control (Fig. 6a); however, this effect was not statistically significant until a higher concentration (100 μ M) of paroxetine was used. Fluoxetine (30 μ M) had no inhibitory effect in the ATP-induced IL-1 β secretion assay and enhanced P2X7-induced IL-1 β secretion to 148 ± 33 % of the ATP control although this did not reach significance (Fig. 6). To rule out an effect of paroxetine or trifluoperazine on protein synthesis of pro-IL-1 β during the priming step with LPS, we performed an additional set of experiments where we introduced paroxetine, A438079 and trifluoperazine 15 min before the addition of ATP. Here, we observed a similar complete inhibition of ATP-induced IL-1 β secretion by TFP and A438079 and a similar reduction in IL-1 β secretion by 30 μ M paroxetine (45.5 ± 17 % of control) which did not reach significance.

Fig. 6 Paroxetine and TFP suppress P2X7-mediated IL-1 β secretion from human monocytes. **a** Purified CD14 positive monocytes (2×10^5 cells/well) from three donors were primed with 100 ng/ml LPS for 4 h in RPMI media containing 1 % FCS. 3 mM ATP was added for 15 min to elicit IL-1 β secretion. Supernatants were collected, frozen at -80 °C and tested by ELISA. Monocytes were treated with drugs during LPS priming step, A-438079 (dark grey), paroxetine (PAR; red) and fluoxetine (FLUOX; blue). Data is presented as % of ATP-induced secretion above LPS. Cells did not secrete IL-1 β in the absence of LPS (mean 36 pg/ml in media-treated cells) and LPS did not induce an appreciable IL-1 β secretion (mean 420 pg/ml). 3 mM ATP elicited a mean IL-1 β secretion of 4826 pg/ml ($n=3$ donors). * $p < 0.05$ by one-way ANOVA with Dunnetts post-test. **b** Purified CD14 monocytes from an additional three donors were treated with LPS (100 ng/ml) for 4 h. Drugs (A438079, PAR or TFP) were applied after the LPS priming step, 15 min before the addition of ATP (3 mM). Cells did not secrete IL-1 β in the absence of LPS (mean 38 pg/ml in media-treated cells) and LPS did not induce an appreciable IL-1 β secretion (mean 481 pg/ml). ATP elicited a mean IL-1 β secretion of 2863 pg/ml ($n=3$ donors) in these experiments. * $p < 0.05$ by one-way ANOVA with Dunnetts post-test

Discussion

P2X7 regulates the secretion of pro-inflammatory cytokines from monocytes and microglia, a process that is potentially linked to mood disorders [4]. The aim of our

present study was to determine the effects of antidepressants and other commonly used psychoactive drugs on recombinant P2X7 responses and receptor-mediated cytokine secretion. Previous studies have reported that several antidepressant compounds inhibit the related ATP-gated ion channel P2X4 [28], a receptor implicated in neuropathic pain and potentially also involved in inflammatory pathways [35–37]. We investigated two common SSRIs, paroxetine and fluoxetine, and a tricyclic antidepressant, clomipramine, amongst several other psychoactive drugs. We chose this panel as they had produced the strongest effects on P2X4 responses in a recombinant expression system [28].

We show here for the first time that paroxetine, but not fluoxetine or clomipramine, inhibits human P2X7. In contrast to paroxetine, fluoxetine and clomipramine induced a potentiation of P2X7-mediated dye uptake responses. Paroxetine and fluoxetine are both known to be potent inhibitors of the serotonin transporter IC₅₀ values of 1.1 and 25 nM, respectively [38]. There are also well-documented effects of antidepressants on multiple neurotransmitter receptors and ion channels including nicotinic acetylcholine receptors [39], 5-HT₃ receptors [40], voltage-gated Na⁺ [41], G-protein-activated inwardly rectifying K⁺ channels [42, 43] and hERG channels [44]. In addition, fluoxetine has been shown to potentiate GABA_A receptors through binding to an allosteric site on this ion channel [45]. Similar to other ion channels, P2X7 may have several allosteric sites capable of binding a broad range of chemical compounds that modulate their activity. The effects of antidepressants on P2X7 in this study were observed at higher concentrations than would be expected from the estimated therapeutic range for treating clinical depression. However, these concentrations are in line with reports of block of other ion channels [39–42].

Comparing the effect of paroxetine on the two different P2X channels, the IC₅₀ value for paroxetine on human P2X7 was an order of magnitude higher than that reported for human P2X4 [28]. We found that paroxetine did not have an inhibitory effect on recombinant rat P2X7 or mouse P2X7 receptors; therefore, similar to a number of other antagonists, this drug demonstrates P2X7 species selectivity [33, 46, 47]. This is also in contrast to the antidepressant effect on P2X4 where paroxetine inhibited both rodent and human P2X4 [28]. The differences in paroxetine IC₅₀ and species selectivity between P2X7 and P2X4 receptors may reflect different modes of interaction between receptor and drug. It has been suggested that antidepressants may inhibit P2X4 by reducing surface expression of the channel through a lysosomal-dependent process [48]. Our experiments suggest paroxetine may have a direct effect on P2X7, since acute application resulted in inhibition of ATP-induced inward currents. Furthermore, P2X7 does not display desensitisation, and internalisation of P2X7 through a lysosomal-dependent pathway has not been demonstrated.

We found that the anti-psychotic agent trifluoperazine hydrochloride had a significant inhibitory effect on human P2X7 responses. Our data is in line with recent findings by Hempel et al., [29] who identified an inhibitory effect of phenothiazine class antipsychotics such as trifluoperazine as allosteric modulators of the human P2X7 receptor. Our calculated IC₅₀ value for TFP on human P2X7 is slightly higher at 6.4 vs 1.8 μM [29]. We also found that TFP had no inhibitory effect at rodent P2X7 receptors. Furthermore, mutation of L95 in rat P2X7 to the human P2X7 equivalent (F) did not increase sensitivity to TFP, suggesting TFP does not bind to the same allosteric antagonist binding site as AZ11645373 [33]. A more extensive mutagenesis study will be required to determine the TFP and paroxetine binding site(s) on human P2X7.

P2X7 is an important regulator of IL-1β secretion from monocytes, macrophages and microglia [2]. There is accumulating evidence of a link between inflammation and mood disorders [5, 6] with pro-inflammatory cytokines such as IL-1β playing a key role in triggering sickness behaviour and inflammation-associated depressive disorders [4, 5]. In this study, we found that paroxetine reduced P2X7-mediated IL-1β secretion from LPS-primed human monocytes from three donors. We have previously shown that the Q460R mutation (rs2230912) is associated with a gain-of-function haplotype of *P2RX7* due to co-inheritance with a gain-of-function SNP (rs1718119) encoding an A348T mutation [14]. We found that paroxetine and TFP had the same inhibitory effect on the recombinant gain-of-function haplotype of human P2X7 (P2X7-4) compared to the wild-type recombinant human P2X7.

In this study, we demonstrate two different drugs with different therapeutic uses having the same inhibitory effect on human P2X7. TFP has been previously demonstrated to inhibit acute inflammation [49] and chronic inflammatory pain [50], potentially through action on CaMKII as a molecular target. However, to the best of our knowledge, TFP is not known to exhibit a marked anti-depressive effect in vivo. Conversely, paroxetine has a known antidepressant effect [38] and may work in some pain models [51] but little is known about its anti-inflammatory effects. Much evidence is available now for inflammatory-type reactions occurring in psychiatric patients [4, 5] but whether anti-inflammatory effects of selected therapeutic agents have any bearing on their clinical effect is not known.

Acknowledgments We thank Dr Ronald Sluyter (University of Wollongong) and Dr Suzanne Rogers (RMIT University, Melbourne) for helpful discussions and Ms Griselda Loza-Diaz (Sydney Medical School Nepean, University of Sydney) for assistance with venipuncture. This work was supported by the National Health and Medical Research Council, Australia (Grant ID 632687 to LS).

References

- Wiley JS et al (2011) The human P2X7 receptor and its role in innate immunity. *Tissue Antigens* 78(5):321–332
- Ferrari D et al (2006) The P2X7 receptor: a key player in IL-1 processing and release. *J Immunol (Baltimore, Md : 1950)* 176(7):3877–3883
- MacKenzie A et al (2001) Rapid secretion of interleukin-1beta by microvesicle shedding. *Immunity* 15(5):825–835
- Dantzer R et al (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* 9(1):46–56
- Miller AH, Maletic V, Raison CL (2010) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. *Biol Psychiatry*: 1–10
- Maes M et al (2012) Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. *BMC Med* 10: 66
- Barden N et al (2006) Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. *Am J Med Genet B Neuropsychiatr Genet* 141B(4):374–382
- Lucae S et al (2006) P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. *Hum Mol Genet* 15(16):2438–2445
- McQuillin A et al (2009) Case-control studies show that a non-conservative amino-acid change from a glutamine to arginine in the P2RX7 purinergic receptor protein is associated with both bipolar- and unipolar-affective disorders. *Mol Psychiatry* 14(6): 614–620
- Soronen P et al (2011) P2RX7 gene is associated consistently with mood disorders and predicts clinical outcome in three clinical cohorts. *Am J Med Genet B Neuropsychiatr Genet* 156B(4):435–447
- Green EK et al (2009) P2RX7: a bipolar and unipolar disorder candidate susceptibility gene? *Am J Med Genet B Neuropsychiatr Genet* 150B(8):1063–1069
- Grigoriu-Serbanescu M et al (2009) Variation in P2RX7 candidate gene (rs2230912) is not associated with bipolar I disorder and unipolar major depression in four European samples. *Am J Med Genet B Neuropsychiatr Genet* 150B(7):1017–1021
- Viikki M et al (2011) P2RX7 polymorphisms Gln460Arg and His155Tyr are not associated with major depressive disorder or remission after SSRI or ECT. *Neurosci Lett* 493(3):127–130
- Stokes L et al (2010) Two haplotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1beta secretion. *FASEB J* 24(8): 2916–2927
- Basso A et al. (2008) Behavioral profile of P2X7 receptor knockout mice in animal models of depression, anxiety: relevance for neuropsychiatric disorders. *Behav Brain Res*: 46
- Csolle C et al. (2012) The absence of P2X7 receptors (P2rx7) on non-haematopoietic cells leads to selective alteration in mood-related behaviour with dysregulated gene expression and stress reactivity in mice. *Int J Neuropsychopharmacol*: 1–21
- Stokes L, Spencer SJ, Jenkins TA (2015) Understanding the role of P2X7 in affective disorders—are glial cells the major players? *Front Cell Neurosci* 9:258
- Coddou C et al (2011) Activation and regulation of purinergic P2X receptor channels. *Pharmacol Rev* 63(3):641–683
- Bartlett R, Stokes L, Sluyter R (2014) The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. *Pharmacol Rev* 66(3):638–675
- Gargett CE, Wiley JS (1997) The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. *Br J Pharmacol* 120(8):1483–1490
- Virginio C et al (1997) Effects of divalent cations, protons and calmidazolium at the rat P2X7 receptor. *Neuropharmacology* 36(9):1285–1294
- Shemon AN et al (2004) Chelerythrine and other benzophenanthridine alkaloids block the human P2X7 receptor. *Br J Pharmacol* 142(6):1015–1019
- Shemon AN et al (2008) Inhibition of the human P2X7 receptor by a novel protein tyrosine kinase antagonist. *Biochem Biophys Res Commun* 365(3):515–520
- Michel AD et al (2006) Species and response dependent differences in the effects of MAPK inhibitors on P2X(7) receptor function. *Br J Pharmacol* 149(7):948–957
- Ma W et al (2009) Pharmacological characterization of pannexin-1 currents expressed in mammalian cells. *J Pharmacol Exp Ther* 328(2):409–418
- Norenberg W et al (2011) Clemastine potentiates the human P2X7 receptor by sensitizing it to lower ATP concentrations. *J Biol Chem* 286(13):11067–11081
- Bhaskaracharya A et al (2014) Probenecid blocks human P2X7 receptor-induced dye uptake via a pannexin-1 independent mechanism. *PLoS ONE* 9(3), e93058
- Nagata K et al (2009) Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief. *Mol Pain* 5: 20
- Hempel C et al (2013) The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor. *Neuropharmacology* 75:365–379
- Kenis G, Maes M (2002) Effects of antidepressants on the production of cytokines. *Int J Neuropsychopharmacol* 5(4):401–412
- Donnelly-Roberts DL et al (2009) Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. *Br J Pharmacol* 157(7):1203–1214
- Bradley HJ et al (2011) Pharmacological properties of the rhesus macaque monkey P2X7 receptor. *Br J Pharmacol* 164(2b):743–754
- Michel AD et al (2008) Identification of regions of the P2X(7) receptor that contribute to human and rat species differences in antagonist effects. *Br J Pharmacol* 155(5):738–751
- Michel AD et al (2009) Mechanism of action of species-selective P2X(7) receptor antagonists. *Br J Pharmacol* 156(8):1312–1325
- Toulme E et al. (2010) On the role of ATP-gated P2X receptors in acute, inflammatory and neuropathic pain. In: Kruger L, Light AR (Eds) *Translational pain research: from mouse to man*. Boca Raton, FL
- Tsuda M et al (2003) P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. *Nature* 424(6950):778–783
- Ulmann L, Hirbec H, Rassendren F (2010) P2X4 receptors mediate PGE2 release by tissue-resident macrophages and initiate inflammatory pain. *EMBO J* 29(14):2290–2300
- Bourin M, Chue P, Guillon Y (2001) Paroxetine: a review. *CNS Drug Rev* 7(1):25–47
- Arias HR et al (2010) Interaction of selective serotonin reuptake inhibitors with neuronal nicotinic acetylcholine receptors. *Biochemistry* 49(27):5734–5742
- Eisensamer B et al (2003) Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. *Mol Psychiatry* 8(12): 994–1007
- Dick IE et al (2007) Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. *J Pain* 8(4):315–324
- Kobayashi T, Washiyama K, Ikeda K (2006) Inhibition of G protein-activated inwardly rectifying K⁺ channels by the antidepressant paroxetine. *J Pharmacol Sci* 102(3):278–287
- Kobayashi T, Washiyama K, Ikeda K (2010) Inhibition of G-protein-activated inwardly rectifying K⁺ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine. *Neuropsychopharmacology* 35(7):1560–1569

44. Jo SH et al (2008) Clomipramine block of the hERG K⁺ channel: accessibility to F656 and Y652. *Eur J Pharmacol* 592(1–3):19–25
45. Robinson RT, Drafts BC, Fisher JL (2003) Fluoxetine increases GABA(A) receptor activity through a novel modulatory site. *J Pharmacol Exp Ther* 304(3):978–984
46. Michel AD, Chambers LJ, Walter DS (2008) Negative and positive allosteric modulators of the P2X(7) receptor. *Br J Pharmacol* 153(4):737–750
47. Stokes L et al (2006) Characterization of a selective and potent antagonist of human P2X(7) receptors, AZ11645373. *Br J Pharmacol* 149(7):880–887
48. Toulme E et al (2010) P2X4 receptors in activated C8-B4 cells of cerebellar microglial origin. *J Gen Physiol* 135(4):333–353
49. Mahmoodi M et al (2009) Effect of trifluoperazine on carrageenan-induced acute inflammation in intact and adrenalectomized rats. *Int J Physiol Pathophysiol Pharmacol* 1(2):150–153
50. Luo F et al (2008) Reversal of chronic inflammatory pain by acute inhibition of Ca²⁺/calmodulin-dependent protein kinase II. *J Pharmacol Exp Ther* 325(1):267–275
51. Zarei M, Sabetkasaei M, Moini Zanjani T (2014) Paroxetine attenuates the development and existing pain in a rat model of neuropathic pain. *Iran Biomed J* 18(2):94–100